First Drug Approved Under New Scheme To Speed Access In Poorer Countries
Seven African Regulators Took Part In The Procedure
Executive Summary
Switzerland’s medicines agency has cleared Ferring’s carbetocin for preventing uterine haemorrhage under the Marketing Authorization for Global Health Products (MAGHP) procedure, which is intended to accelerate the approval of new products in low- and middle-income countries.
You may also be interested in...
EMA Explains Procedure For Parallel Review Of Drugs For EU And Non-EU Markets
Companies can get the European Medicines Agency’s scientific opinion for their products’ use in EU and non-EU countries at about the same time.
New Deal To Boost Progress On African Medicines Agency
A new agreement between the WHO and the African Union is expected to strengthen efforts to create the new African Medicines Agency, following the endorsement of the AMA treaty earlier this year.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.